Compare CCM & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | LSTA |
|---|---|---|
| Founded | 1997 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 20.9M |
| IPO Year | 2009 | N/A |
| Metric | CCM | LSTA |
|---|---|---|
| Price | $4.25 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 3.2K | ★ 23.9K |
| Earning Date | 09-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,056,841.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $1.81 |
| 52 Week High | $10.77 | $4.20 |
| Indicator | CCM | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 43.94 |
| Support Level | $4.12 | $1.97 |
| Resistance Level | $4.99 | $2.15 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 48.96 | 46.87 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.